QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.

被引：0
|
作者：
Gavai, AV [1 ]
Vaz, RJ [1 ]
Santone, K [1 ]
Chandrasena, G [1 ]
Nayeem, A [1 ]
机构：
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2003年 / 226卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
354-MEDI
引用
收藏
页码：U66 / U66
页数：1
相关论文
共 50 条
  • [31] Influence of CYP3A4 and CYP2D6 inhibition on fesoterodine treatment
    Sachse, R
    Cawello, W
    Horstmann, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1186 - 1186
  • [32] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [33] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation:: a study of mutations CYP2D6*3 and CYP2D6*4
    Monek, O
    Paintaud, G
    Bechtel, Y
    Miguet, JP
    Mantion, G
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) : 47 - 52
  • [34] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4
    O. Monek
    G. Paintaud
    Y. Bechtel
    J. P. Miguet
    G. Mantion
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 1998, 54 : 47 - 52
  • [35] CYP2D6*11 and challenges in clinical genotyping of the highly polymorphic CYP2D6 gene
    Skierka, Jennifer M.
    Walker, Denise L.
    Peterson, Sandra E.
    O'Kane, Dennis J.
    Black, John Logan, III
    PHARMACOGENOMICS, 2012, 13 (08) : 951 - 954
  • [36] EVALUATION OF A TEMPLATE MODEL OF THE CYP2D6 ACTIVE-SITE BY EXPERIMENTAL TESTING OF COMPOUNDS WITH RECOMBINANT HUMAN CYP2D6
    BULSARA, D
    ACKLAND, MJ
    DUNCAN, JN
    REES, SA
    ELLIS, SW
    LENNARD, MS
    TUCKER, GT
    FASEB JOURNAL, 1994, 8 (07): : A1244 - A1244
  • [37] Codeine abuse liability is modified by CYP2D6 inhibition.
    Romach, MK
    Kathiramalainathan, K
    Kaplan, HL
    Busto, UE
    Tyndale, RF
    Sellers, EM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PI107 - PI107
  • [38] Differentially altered metabolism and inhibition of CYP2D6*10.
    Ramamoorthy, Y
    Suh, N
    Tyndale, RF
    Sellers, EM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 121 - 121
  • [39] Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation
    Zourkova, A.
    Jurica, J.
    Hadasova, E. McCaskey
    Pulkrabkova, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S328 - S329
  • [40] Irreversible inhibition of CYP2D6 by (-)-chloroephedrine, a possible impurity in methamphetamine
    Rege, B
    Carter, KM
    Sarkar, MA
    Kellogg, GE
    Soine, WH
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) : 1337 - 1343
12345